GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edgewise Therapeutics Inc (NAS:EWTX) » Definitions » 3-Year Revenue Growth Rate

EWTX (Edgewise Therapeutics) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Edgewise Therapeutics 3-Year Revenue Growth Rate?

Edgewise Therapeutics's Revenue per Share for the three months ended in Dec. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Edgewise Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Edgewise Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edgewise Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edgewise Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Edgewise Therapeutics's 3-Year Revenue Growth Rate falls into.


;
;

Edgewise Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Edgewise Therapeutics  (NAS:EWTX) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Edgewise Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Edgewise Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Edgewise Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edgewise Therapeutics Inc (NAS:EWTX) » Definitions » 3-Year Revenue Growth Rate
Comparable Companies
VCEL CPRX BEAM MIRM ARWR IBRX MLTX KYMR FOLD PTGX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
1715 38th Street, Boulder, CO, USA, 80301
Website
https://www.edgewisetx.com
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Executives
Alan J Russell director, officer: Chief Scientific Officer 3415 COLORADO AVE, BOULDER CO 80303
Kevin Koch director, officer: President and CEO 3200 WALNUT ST, BOULDER CO 80301
Behrad Derakhshan officer: Chief Business Officer 3415 COLORADO AVE., BOULDER CO 80303
Joanne M. Donovan officer: CMO C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ. BLDG. 1400E SUITE B14202, CAMBRIDGE MA 02139
Marc Semigran officer: Chief Development Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
John R Moore officer: General Counsel 3200 WALNUT ST, BOULDER CO 80301
R Michael Carruthers officer: Chief Financial Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson director, 10 percent owner C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Jonathan C Fox director C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Orbimed Capital Gp Vi Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan D Root director 2735 SAND HILL ROAD, MENLO PARK CA 94025
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017